Mysterious topical IDP-115 being trialled

Written by on April 26, 2008 in clinical trials, Rosacea Topicals with 3 Comments

A seemingly new topical treatment for rosacea is being trialled by Dow Pharmaceutical Sciences. The product is being evaluated firstly for the number of inflammatory lesions and global severity, and secondly for redness. This, along with the trial lasting 12 weeks, and the large size of the trial leads me to guess that IDP-115 is a metronidazole or azelaic acid variant.

Google hasn’t found any clues to IDP-115 or Dow Pharmaceutical Sciences. If you know anything more about this product, please leave a comment below.

From Clinical Trial NCT00667173

A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With Rosacea. The purpose of this study is to assess the safety and effectiveness of IDP-115 in treating patients with rosacea.

Update: I was able to find a web reference  (since expired) that suggested that IDP-115 is a sunscreen with another active ingredient, and is now owned by Valeant Pharmaceuticals International

A number of late stage dermatology product candidates in development were acquired as part of the acquisition of Dow on December 31, 2008. These include, but are not limited to:

DP-115: IDP-115 is a product that combines an active ingredient with sunscreen agents providing SPF for the treatment of rosacea. IDP-115 has completed Phase II clinical trials. Rosacea is characterized by erythema that begins on the central face and can spread to the cheeks, nose, and forehead and less commonly affect the neck, chest, ears, and scalp.

The 2009 Annual Report by Valeant further clarifies that IDP-115 contains “an established anti-rosacea active ingredient”, suggesting metronidazole as the main active ingredient.

This being so, IDP-115 could be similar to Rosasol, another formulation containing metronidazole and a suncreen.

Read more about: clinical trials, Rosacea Topicals

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

3 Reader Comments

  1. Alex says:

    Based on Dow Pharmaceutical Sciences corporate website, they are likely to conduct this study for another company.

  2. Hi Alex,

    It makes it even more mysterious that whoever has the new product is using an intermediate party to undertake the trial. Makes me think that it must be one of the existing big players – to be bothered with a trial of this size and outsourcing the logistics.


  3. susan says:

    I had a really bad, red,swollen nose at the weekend..the worst ever..As far as i know there are no over the counter products in the uk for us sufferers.There are so many strong medications and lotions that one can get at the chemist now…eg morning after pill….is there anything i could have bought?i find it annoying that i coulnt self help via the chemist…

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.